Compare $APVO vs $ORGS | Chartloom

Compare

$APVO vs $ORGS

Aptevo Therapeutics Inc · Orgenesis Inc

APVO

Aptevo Therapeutics Inc

ORGS

Orgenesis Inc

Compare $APVO vs $ORGS

Comparing Aptevo Therapeutics Inc and Orgenesis Inc

APVOAptevo Therapeutics Inc

ORGSOrgenesis Inc

APVOAptevo Therapeutics Inc

Market cap

$2M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-80.9%

52W performance

-94.2%

FCF yield

-1132.6%

ORGSOrgenesis Inc

Market cap

$3M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-92.8%

YTD performance

133.3%

52W performance

-56.3%

FCF yield

-505.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

APVO

ORGS

Detailed metrics comparison

APVO

Aptevo Therapeutics Inc

ORGS

Orgenesis Inc

Market Cap

APVO$2M

ORGS$3M

Enterprise Value

APVO$-8M

ORGS$20M

Price

APVO$1.79

ORGS$0.35

P/E Ratio

APVON/A

ORGSN/A

P/S Ratio

APVO0.25x

ORGS3.31x

EV/Sales

APVO-0.51x

ORGS19.39x

EV/EBITDA

APVO-0.91x

ORGS0.00x

P/B Ratio

APVO0.53x

ORGS0.28x

P/FCF Ratio

APVON/A

ORGSN/A

EV/FCF

APVO0.30x

ORGS-1.16x

PEG Ratio

APVON/A

ORGSN/A

Forward P/E (NTM)

APVON/A

ORGSN/A

Forward P/S (NTM)

APVON/A

ORGSN/A

Revenue (TTM)

APVO$0

ORGS$1M

Revenue Growth (YoY)

APVON/A

ORGS-92.8%

Forward Rev Growth

APVO206.8%

ORGS0.0%

Gross Margin (TTM)

APVO51.4%

ORGS-86.3%

Operating Margin (TTM)

APVO0.0%

ORGS0.0%

EBITDA Margin (TTM)

APVO0.0%

ORGS-1868.2%

Net Margin (TTM)

APVO0.0%

ORGS-4653.6%

FCF Margin (TTM)

APVON/A

ORGS-1675.3%

Net Income (TTM)

APVO$-28M

ORGS$-48M

FCF (TTM)

APVO$-25M

ORGS$-17M

EPS (TTM)

APVO-$23.47

ORGS-$9.58

ROE (TTM)

APVO-20149.0%

ORGS-10936.0%

ROA (TTM)

APVO-11921.0%

ORGS-20820.0%

ROIC (TTM)

APVO-20149.0%

ORGS-5864.0%

Cash

APVO$10M

ORGS$78K

Debt

APVO$0

ORGS$17M

Net Cash/Debt

APVO$10M

ORGS$-17M

Current Ratio (TTM)

APVO2.08x

ORGS0.03x

Quick Ratio (TTM)

APVO1.98x

ORGS0.03x

Debt/Equity (TTM)

APVO0.00x

ORGS1.73x

Debt/Assets (TTM)

APVO0.0%

ORGS0.0%

Interest Coverage (TTM)

APVON/A

ORGSN/A

Net Debt/EBITDA (TTM)

APVO0.00x

ORGS0.00x

Beta

APVO1.68

ORGS3.73

52W Performance

APVO-94.2%

ORGS-56.3%

YTD Performance

APVO-80.9%

ORGS133.3%

% from 52W High

APVO-94.6%

ORGS-65.0%

% from 52W Low

APVO30.7%

ORGS34900.0%

Asset Turnover (TTM)

APVO0.22x

ORGS0.04x

FCF Yield (TTM)

APVO-1132.6%

ORGS-505.5%

Earnings Yield (TTM)

APVO-1254.8%

ORGS-1404.2%

Dividend Yield (TTM)

APVON/A

ORGSN/A

Rule of 40

APVO0.0

ORGS-1,768.0

EV/GP/RG

APVON/A

ORGSN/A

Ticker research

View APVO research View ORGS research

Metric	APVO Aptevo Therapeutics Inc	ORGS Orgenesis Inc
Market & Valuation
Market Cap	$2M	$3M
Enterprise Value	$-8M	$20M
Price	$1.79	$0.35
P/E Ratio	N/A	N/A
P/S Ratio	0.25x	3.31x
EV/Sales	-0.51x	19.39x
EV/EBITDA	-0.91x	0.00x
P/B Ratio	0.53x	0.28x
P/FCF Ratio	N/A	N/A
EV/FCF	0.30x	-1.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$1M
Revenue Growth (YoY)	N/A	-92.8%
Forward Rev Growth	206.8%	0.0%
Profitability
Gross Margin (TTM)	51.4%	-86.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-1868.2%
Net Margin (TTM)	0.0%	-4653.6%
FCF Margin (TTM)	N/A	-1675.3%
Net Income (TTM)	$-28M	$-48M
FCF (TTM)	$-25M	$-17M
EPS (TTM)	-$23.47	-$9.58
ROE (TTM)	-20149.0%	-10936.0%
ROA (TTM)	-11921.0%	-20820.0%
ROIC (TTM)	-20149.0%	-5864.0%
Financial Health
Cash	$10M	$78K
Debt	$0	$17M
Net Cash/Debt	$10M	$-17M
Current Ratio (TTM)	2.08x	0.03x
Quick Ratio (TTM)	1.98x	0.03x
Debt/Equity (TTM)	0.00x	1.73x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.68	3.73
52W Performance	-94.2%	-56.3%
YTD Performance	-80.9%	133.3%
% from 52W High	-94.6%	-65.0%
% from 52W Low	30.7%	34900.0%
Efficiency & Yields
Asset Turnover (TTM)	0.22x	0.04x
FCF Yield (TTM)	-1132.6%	-505.5%
Earnings Yield (TTM)	-1254.8%	-1404.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-1,768.0
EV/GP/RG	N/A	N/A
Ticker research	View APVO research	View ORGS research

Valuation

P/S Ratio

APVO

0.25x

ORGS

3.31x

EV/FCF

ORGS

-1.16x

APVO

0.30x

Growth & revenue

Revenue Growth TTM

ORGS

-92.8%

Forward Revenue Growth

APVO

206.8%

ORGS

0.0%

Profitability & performance

Gross Margin

APVO

51.4%

ORGS

-86.3%

ROE

ORGS

-10936.0%

APVO

-20149.0%

FCF Yield %

ORGS

-505.5%

APVO

-1132.6%

52-Week Performance

ORGS

-56.3%

APVO

-94.2%

Detailed metrics comparison

APVO

Aptevo Therapeutics Inc

ORGS

Orgenesis Inc

Market Cap

APVO$2M

ORGS$3M

Enterprise Value

APVO$-8M

ORGS$20M

Price

APVO$1.79

ORGS$0.35

P/E Ratio

APVON/A

ORGSN/A

P/S Ratio

APVO0.25x

ORGS3.31x

EV/Sales

APVO-0.51x

ORGS19.39x

EV/EBITDA

APVO-0.91x

ORGS0.00x

P/B Ratio

APVO0.53x

ORGS0.28x

P/FCF Ratio

APVON/A

ORGSN/A

EV/FCF

APVO0.30x

ORGS-1.16x

PEG Ratio

APVON/A

ORGSN/A

Forward P/E (NTM)

APVON/A

ORGSN/A

Forward P/S (NTM)

APVON/A

ORGSN/A

Revenue (TTM)

APVO$0

ORGS$1M

Revenue Growth (YoY)

APVON/A

ORGS-92.8%

Forward Rev Growth

APVO206.8%

ORGS0.0%

Gross Margin (TTM)

APVO51.4%

ORGS-86.3%

Operating Margin (TTM)

APVO0.0%

ORGS0.0%

EBITDA Margin (TTM)

APVO0.0%

ORGS-1868.2%

Net Margin (TTM)

APVO0.0%

ORGS-4653.6%

FCF Margin (TTM)

APVON/A

ORGS-1675.3%

Net Income (TTM)

APVO$-28M

ORGS$-48M

FCF (TTM)

APVO$-25M

ORGS$-17M

EPS (TTM)

APVO-$23.47

ORGS-$9.58

ROE (TTM)

APVO-20149.0%

ORGS-10936.0%

ROA (TTM)

APVO-11921.0%

ORGS-20820.0%

ROIC (TTM)

APVO-20149.0%

ORGS-5864.0%

Cash

APVO$10M

ORGS$78K

Debt

APVO$0

ORGS$17M

Net Cash/Debt

APVO$10M

ORGS$-17M

Current Ratio (TTM)

APVO2.08x

ORGS0.03x

Quick Ratio (TTM)

APVO1.98x

ORGS0.03x

Debt/Equity (TTM)

APVO0.00x

ORGS1.73x

Debt/Assets (TTM)

APVO0.0%

ORGS0.0%

Interest Coverage (TTM)

APVON/A

ORGSN/A

Net Debt/EBITDA (TTM)

APVO0.00x

ORGS0.00x

Beta

APVO1.68

ORGS3.73

52W Performance

APVO-94.2%

ORGS-56.3%

YTD Performance

APVO-80.9%

ORGS133.3%

% from 52W High

APVO-94.6%

ORGS-65.0%

% from 52W Low

APVO30.7%

ORGS34900.0%

Asset Turnover (TTM)

APVO0.22x

ORGS0.04x

FCF Yield (TTM)

APVO-1132.6%

ORGS-505.5%

Earnings Yield (TTM)

APVO-1254.8%

ORGS-1404.2%

Dividend Yield (TTM)

APVON/A

ORGSN/A

Rule of 40

APVO0.0

ORGS-1,768.0

EV/GP/RG

APVON/A

ORGSN/A

Ticker research

View APVO research View ORGS research

Metric	APVO Aptevo Therapeutics Inc	ORGS Orgenesis Inc
Market & Valuation
Market Cap	$2M	$3M
Enterprise Value	$-8M	$20M
Price	$1.79	$0.35
P/E Ratio	N/A	N/A
P/S Ratio	0.25x	3.31x
EV/Sales	-0.51x	19.39x
EV/EBITDA	-0.91x	0.00x
P/B Ratio	0.53x	0.28x
P/FCF Ratio	N/A	N/A
EV/FCF	0.30x	-1.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$1M
Revenue Growth (YoY)	N/A	-92.8%
Forward Rev Growth	206.8%	0.0%
Profitability
Gross Margin (TTM)	51.4%	-86.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-1868.2%
Net Margin (TTM)	0.0%	-4653.6%
FCF Margin (TTM)	N/A	-1675.3%
Net Income (TTM)	$-28M	$-48M
FCF (TTM)	$-25M	$-17M
EPS (TTM)	-$23.47	-$9.58
ROE (TTM)	-20149.0%	-10936.0%
ROA (TTM)	-11921.0%	-20820.0%
ROIC (TTM)	-20149.0%	-5864.0%
Financial Health
Cash	$10M	$78K
Debt	$0	$17M
Net Cash/Debt	$10M	$-17M
Current Ratio (TTM)	2.08x	0.03x
Quick Ratio (TTM)	1.98x	0.03x
Debt/Equity (TTM)	0.00x	1.73x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.68	3.73
52W Performance	-94.2%	-56.3%
YTD Performance	-80.9%	133.3%
% from 52W High	-94.6%	-65.0%
% from 52W Low	30.7%	34900.0%
Efficiency & Yields
Asset Turnover (TTM)	0.22x	0.04x
FCF Yield (TTM)	-1132.6%	-505.5%
Earnings Yield (TTM)	-1254.8%	-1404.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-1,768.0
EV/GP/RG	N/A	N/A
Ticker research	View APVO research	View ORGS research